Want to join the trial?
Choose a location to contact our Clinical Trial Coordinator and to discuss potential opportunities.
Contact to discuss potential opportunities.
Email CoordinatorOverview
Krystal 007: A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Description
This Phase 2 study evaluates the safety, pharmacokinetics, and clinical activity of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation.
Learn more at clinicaltrials.gov
Eligibility Criteria
Inclusion
- Histologically confirmed diagnosis of NSCLC (squamous or nonsquamous) with KRAS G12C mutation and known PD-L1 Tumor Proportion Score (TPS) score.
- Unresectable or metastatic disease
Exclusion
- Prior systemic treatment for locally advanced or metastatic NSCLC including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C mutation (e.g., AMG 510).
- Active brain metastases.